Axicabtagene ciloleucel approved for second-line treatment of large B-cell lymphoma
Axicabtagene ciloleucel (axi-cel; Yescarta) was approved for treatment of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or ...
Read more
